This invention is directed to selective antagonists of A
2A
and/or A
2B
adenosine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
A new series of 4-(1,3-dialkyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)benzenesulfonamides has been identified as potent AZB adenosine receptor antagonists. The products have been evaluated for their binding affinities for the human A(2B), A(1) and A(3) adenosine receptors. 6-(4-[4-(4-Bromobenzyl)piperazin-1-yl]sulfonyl}phenyl)-1,3-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione (16) showed a high affinity for the AZB adenosine receptor (IC50 = 1 nM) and selectivity (A(1): 183x; A(30): 12660x). Synthesis and SAR of this novel class of compounds showing improved absorption properties is presented herein. (c) 2006 Elsevier Ltd. All rights reserved.